Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: AtaiBeckley Inc.

Market Cap 1.43B 1.23B 1.14B 1.07B 1.99B 136B 2.03B 13.5B 5.24B 65.83B 5.36B 5.24B 229B P/E ratio 2026 *
-9.12x
P/E ratio 2027 * -8.83x
Enterprise value 1.27B 1.1B 1.01B 946M 1.77B 121B 1.8B 11.98B 4.65B 58.42B 4.76B 4.65B 203B EV / Sales 2026 *
1,142x
EV / Sales 2027 * 4,303x
Free-Float
97.64%
Yield 2026 *
-
Yield 2027 * -
1 day+0.64%
1 week-12.80%
Current month-12.80%
1 month-2.23%
3 months-4.59%
6 months-8.78%
Current year-3.42%
1 week 3.76
Extreme 3.76
4.74
1 month 3.76
Extreme 3.76
5
Current year 3.26
Extreme 3.265
5.51
1 year 2
Extreme 2
6.75
3 years 1.02
Extreme 1.025
6.75
5 years 1.02
Extreme 1.025
22.91
10 years 1.02
Extreme 1.025
22.91
Date Insider Type Main position Quantity % Market Cap.
06-03Free

Director

208,063 0.0565%
06-03Free

Director

121,968 0.0331%
06-03Free

Founder

121,968 0.0331%
Change 5-day change 1-year change 3-year change Capi.($)
+0.64%-12.80%+75.56%+123.16% 1.43B
+0.61%+1.96%-13.54%-11.27% 43.4B
-3.79%-7.21%+244.78%+471.87% 31.79B
-0.37%+2.26%+16.62%-12.07% 31.09B
-0.69%-4.48%+1.17%+25.00% 29.81B
+6.65%-5.00%+11.42%+15.34% 24.46B
+1.26%+6.51%+11.87%+10.48% 13.19B
+1.49%+5.61%+55.64%+118.37% 13.33B
+0.39%-0.63% - - 13.24B
-1.17%+0.75%+101.89%+78.66% 12.33B
Average +0.52%-1.34%+56.16%+91.06% 21.41B
Weighted average by Cap. +0.32%-0.10%+51.22%+90.22%

Financials

2026 *2027 *
Net sales 1.11M 959K 884K 828K 1.55M 106M 1.58M 10.48M 4.07M 51.14M 4.16M 4.07M 178M 300K 260K 239K 224K 419K 28.61M 426K 2.84M 1.1M 13.84M 1.13M 1.1M 48.08M
Net income -154M -134M -123M -115M -216M -14.73B -219M -1.46B -567M -7.12B -580M -567M -24.75B -165M -142M -131M -123M -230M -15.71B -234M -1.56B -604M -7.6B -618M -605M -26.4B
Net Debt -160M -139M -128M -120M -224M -15.3B -228M -1.52B -589M -7.4B -603M -590M -25.72B -136M -118M -109M -102M -190M -12.99B -194M -1.29B -500M -6.28B -512M -501M -21.84B
Logo AtaiBeckley Inc.
AtaiBeckley Inc is a clinical-stage biotechnology company focused on developing rapid-acting, durable and convenient mental health treatments. The Company’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 (R-MDMA HCI) for social anxiety disorder. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. BPL-003 is a proprietary synthetic intranasal formulation of mebufotenin benzoate being developed as a potential treatment for people living with TRD. VLS-01 is a proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT) being developed as a potential treatment for people living with TRD. EMP-01 is an oral formulation of R-MDMA, being developed as a potential treatment for people living with social anxiety disorder.
Employees
99
Date Price Change Volume
10/06/26 3.950 $ +1.54% 884,842
09/06/26 3.890 $ +2.10% 5,405,401
08/06/26 3.810 $ -3.54% 4,929,036
05/06/26 3.950 $ -12.22% 9,240,989
04/06/26 4.500 $ -0.66% 4,553,833
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
3.890USD
Average target price
14.00USD
Spread / Average Target
+259.90%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATAI Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
BENEFIT NOW